Biological ActivityGLYX 13 is a NMDA receptor partial agonist that acts at the glycine site. Simultaneously acts as a promoter of the induction of long-term potentiation (LTP) and as a suppressor of long-term depression (LTD). Also promotes VGF and BDNF release and increases ERK/mTOR signaling. Exhibits nootropic, neuroprotective and antinociceptive activity, and enhances learning, memory and cognition in vivo. Brain penetrant.
(Modifications: Thr-4 = C-terminal amide)
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
GLYX-13: A monoclonal antibody-derived peptide that acts as an N-MthD.-aspartate receptor modulator.
Moskal et al.
Antinociceptive action of GLYX-13: a N-MthD.-aspartate receptor glycine site partial agonist.
Wood et al.
The N-MthD.-aspartate receptor modulator GLYX-13 enhances learning and memory, in young adult and learning impaired aging rats.
Burgdorf et al.
Citation for GLYX 13
The citations listed below are publications that use Tocris products. Selected citations for GLYX 13 include:
1 Citation: Showing 1 - 1
ERK/mTOR signaling may underlying the antidepressant actions of rapastinel in mice.
Authors: Shen Et al.
No product specific FAQs exist for this product, however you mayView all Peptide FAQs
Reviews for GLYX 13
There are currently no reviews for this product. Be the first to review GLYX 13 and earn rewards!
Have you used GLYX 13?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image